Immunotherapy Before Standard Treatment Shows Striking Results in Nasopharyngeal Cancer

Nasopharyngeal carcinoma, a malignancy arising in the uppermost portion of the throat behind the nose, occupies an unusual position in oncology. It is rare in most of the world yet strikingly common in southern China and Southeast Asia, where it ranks among the most frequently diagnosed head and neck cancers. The tumor is tightly linked to Epstein-Barr virus infection, and because of its deep anatomical location and pronounced sensitivity to radiation, the standard of care for locally advanced disease has long been platinum-based chemotherapy combined with intensity-modulated radiotherapy. Despite decades of refinement of this approach, a meaningful proportion of patients still relapse, and the toxicity of intensive chemoradiation remains a clinical burden. A new prospective study from Huizhou Central People’s Hospital in Guangdong, China, published in BMC Cancer, now reports encouraging results from an exploratory regimen that adds a PD-1 checkpoint inhibitor to the treatment sequence.

The drug at the center of the trial is camrelizumab, a humanized monoclonal antibody developed in China that blocks the programmed cell death protein 1, or PD-1, receptor on T lymphocytes. PD-1 functions as a molecular brake on the immune system; when tumor cells engage it through its ligand PD-L1, cytotoxic T cells that would otherwise recognize and destroy malignant cells become functionally exhausted. Checkpoint inhibitors release this brake, restoring antitumor immunity. Camrelizumab has already earned regulatory approval in China for several cancers, including recurrent or metastatic nasopharyngeal carcinoma, but its role earlier in the disease course, before and alongside definitive chemoradiotherapy, had not been prospectively defined. The new study was designed to fill exactly that gap.

The trial, registered as ChiCTR2500102158, enrolled thirty patients with histologically confirmed locally advanced nasopharyngeal carcinoma between September 2022 and February 2025. The treatment strategy followed a sequential logic familiar from other head and neck cancer protocols but with an immunological twist. Patients first received induction chemotherapy combined with camrelizumab, a neoadjuvant phase intended to shrink the tumor and, crucially, to prime the immune system while the tumor burden was still substantial enough to supply antigen. This was followed by concurrent chemoradiotherapy, the established definitive treatment, delivered with intensity-modulated radiation techniques that sculpt high doses around the gross tumor volume and clinical target volumes while sparing nearby organs such as the parotid glands and spinal cord.

The primary endpoint was the complete response rate after neoadjuvant therapy, a deliberately ambitious measure for a phase before surgery or definitive radiation has even begun. The results exceeded what conventional induction chemotherapy alone has typically achieved. After the camrelizumab-chemotherapy phase, 23.3 percent of patients had already achieved a complete response, meaning no detectable residual disease on response assessment. The objective response rate, which combines complete and partial responses, reached 96.7 percent, and the disease control rate was 100 percent, indicating that every patient derived at least some measurable benefit from the initial phase of treatment.

The numbers improved further after definitive therapy. Among the twenty-nine patients evaluable at sixteen weeks following concurrent chemoradiotherapy, twenty-seven had achieved a complete response and two had partial responses, corresponding to a complete response rate of 93.1 percent and objective response and disease control rates of 100 percent. For a disease in which residual or recurrent disease after standard treatment remains a persistent threat, a near-universal complete response rate at early assessment is a striking signal, even in a small exploratory cohort. With a median follow-up of twenty-nine months, only one patient in the entire study developed a regional recurrence, and the estimated two-year overall survival rate was 100 percent, with progression-free survival estimated at 95.5 percent.

Efficacy, however, is only half of the equation in any trial that layers an immunotherapy onto an already toxic regimen. The safety findings were therefore closely scrutinized. Grade III to IV acute adverse events, the severe toxicities that can interrupt treatment or require hospitalization, occurred in nine patients, or 30 percent of the cohort. This figure is notable for being compatible with the toxicity profile expected of intensive chemoradiotherapy itself, suggesting that the addition of camrelizumab did not dramatically amplify the burden of severe side effects. The most common toxicity attributable specifically to camrelizumab was a distinctive dermatological phenomenon known as reactive cutaneous capillary endothelial proliferation, or RCCEP, which was observed in twelve patients, all at grade 1 or 2.

RCCEP is a signature adverse effect of camrelizumab that has intrigued researchers since the drug’s early development. It manifests as small, bright-red, ruby-like papules on the skin, thought to arise from immune-mediated proliferation of capillary endothelial cells rather than from direct tissue damage. The condition is generally self-limiting and rarely requires more than symptomatic management or dose modification, and its appearance has in some analyses been correlated with treatment response. In this study, no severe immune-related adverse events were reported at all, a finding of considerable importance because checkpoint inhibitors can occasionally trigger pneumonitis, hepatitis, colitis, endocrinopathies, or myocarditis that are potentially life-threatening. The absence of such events in this cohort, while reassuring, will need confirmation in larger randomized populations before the safety conclusion can be considered definitive.

The scientific rationale for combining immunotherapy with induction chemotherapy deserves attention, because the sequencing is not arbitrary. Chemotherapy is not merely cytotoxic; at appropriate doses it can promote immunogenic cell death, releasing tumor antigens and danger signals that facilitate dendritic cell activation and T-cell priming. Radiotherapy likewise can convert the tumor into an in situ vaccine, increasing antigen presentation and inflammatory signaling within the irradiated tumor microenvironment. Administering a PD-1 inhibitor during the induction phase may therefore capitalize on a window in which the immune system is being actively stimulated against tumor antigens, potentially generating durable memory T-cell populations that continue to surveil for residual disease long after treatment ends. The exceptionally low recurrence rate observed at two years is consistent with, though certainly not proof of, such a mechanism.

The authors and outside observers alike caution that this was an exploratory, single-arm, single-institution study of thirty patients, without a randomized comparator. Historical response rates for induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma are already respectable, and cross-trial comparisons are notoriously unreliable because of differences in staging, imaging, and patient selection. The complete response rate of 23.3 percent after induction is nonetheless higher than figures commonly reported for chemotherapy alone, and the favorable toxicity profile strengthens the case that the regimen is feasible. Larger phase II and phase III trials with randomized designs, longer follow-up, and rigorous immune-related adverse event monitoring will be required to determine whether the addition of camrelizumab genuinely improves survival or merely accelerates early tumor shrinkage.

Nevertheless, the study adds momentum to a broader shift in head and neck oncology, in which checkpoint inhibitors are migrating from the salvage setting of recurrent and metastatic disease into first-line, treatment-intensification strategies. Nasopharyngeal carcinoma is a particularly attractive target for this approach because it is an Epstein-Barr virus-associated, inflamed, PD-L1-expressing tumor type that has already demonstrated sensitivity to immunotherapy in advanced stages. If the promising safety and efficacy signals from this prospective cohort are validated in larger trials, patients with locally advanced disease could one day receive a short course of immunotherapy-enhanced induction treatment that eradicates microscopic disease earlier, reduces the risk of distant spread, and preserves the curative power of precisely delivered radiotherapy. For now, the Huizhou results stand as an encouraging proof of concept that the immune system can be enlisted at the very beginning of the fight against one of the region’s most consequential cancers.

Subject of Research: Safety and efficacy of camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

Article Title: An exploratory study of safety and efficacy of camrelizumab plus induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

Article References: Chen, T., Tian, Y., Xiao, W., Lan, P., Jiang, X., Lv, J., Zhou, H., Peng, D., & Lan, Y. (2026). An exploratory study of safety and efficacy of camrelizumab plus induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-17010-1

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17010-1

Keywords: nasopharyngeal carcinoma, camrelizumab, immunotherapy, PD-1 inhibitor, induction chemotherapy, concurrent chemoradiotherapy, complete response, adverse events, RCCEP, clinical trial, oncology, radiotherapy